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Abstract: In the search for new microbial antibacterial secondary metabolites, two new
compounds (1 and 2) were isolated from culture broths of Penicillium spathulatum Em19.
Structure determination by nuclear magnetic resonance and mass spectrometry identified
the compounds as 6,7-dihydroxy-5,10-dihydropyrrolo[1,2-b]isoquinoline-3-carboxylic acid (1,
spathullin A) and 5,10-dihydropyrrolo[1,2-b]isoquinoline-6,7-diol (2, spathullin B). The two
compounds displayed activity against both Gram-negative and -positive bacteria, including Escherichia
coli, Acinetobacter baumannii, Enterobacter cloacae, Klebsiella pneumonia, Pseudomonas aeruginosa,
and Staphylococcus aureus. Compound 2 was more potent than 1 against all tested pathogens,
with minimal inhibitory concentrations down to 1 µg/mL (5 µM) against S. aureus, but 2 was
also more cytotoxic than 1 (50% inhibitory concentrations 112 and 11 µM for compounds 1
and 2, respectively, towards Huh7 cells). Based on stable isotope labelling experiments and a
literature comparison, the biosynthesis of 1 was suggested to proceed from cysteine, tyrosine and
methionine via a non-ribosomal peptides synthase like enzyme complex, whereas compound 2 was
formed spontaneously from 1 by decarboxylation. Compound 1 was also easily oxidized to the
1,2-benzoquinone 3. Due to the instability of compound 1 and the toxicity of 2, the compounds are of
low interest as possible future antibacterial drugs.
Keywords: antibiotic resistance; antibacterial secondary metabolites; secondary metabolism;
Penicillium; isoquinoline alkaloids; dehydroalanine
1. Introduction
The global spreading of bacterial resistance to existing antibiotics is a severe and escalating
problem to humanity, as frequently pointed out by many authorities and organizations, e.g., the report
from WHO’s Global Antimicrobial Resistance Surveillance System (GLASS) [1]. Effective treatment
of bacterial infections is one cornerstone in modern society, and the spread of antibiotic resistance
will seriously limit the possibilities to treat simple infections. Antibiotic resistance will also severely
limit surgery and organ transplantation [2]. Due to the spread of antibiotic resistance, there is a great
need for new antibiotics, and in particular, drugs with new mechanisms of action. Already in 2010,
the Infectious Diseases Society of America (IDSA) launched the “10 × ‘20 Initiative”, which seeks a
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global commitment for the development of ten new systemic antibiotic drugs by 2020 [3]. The US
Food and Drug Administration (FDA) has, since 2010, approved 20 new molecular entities for the
treatment of bacterial infections [4]. Of these, however, only the macrolide antibiotic fidaxomicin
(FDA approved in May 2011) has a new target, the bacterial RNA polymerase “switch region” [5],
whereas the remainder are analogues to existing types of drugs, or combinations with new versions of
beta-lactamase inhibitors. Thus, there is a great and unmet need for new antibacterial drugs, and in
particular, drugs with new mechanisms of action [6].
The majority of antibiotics used today and in the past are either natural products of microbial origin
or developed from such molecules, and microorganisms are still considered as very promising sources
for finding new antibacterial secondary metabolites. Among many important microbial taxa for the
production of antibacterial compounds, the 300+ species of the genus Penicillium have been the source
for more than 2000 secondary metabolites [7], as exemplified by benzylpenicillin (penicillin G) [8],
the indole alkaloid brevianamide A [9], the polyketide griseofulvin [10], the isocoumarin derivative
ochratoxin A [11], and the steroid wortmannin [12].
We are currently searching for new antibacterial compounds produced by fungi and bacteria, in a
screening effort at the Swedish University of Agricultural Sciences, with the overall goal of finding
candidates for new antibiotics. The present paper describes the isolation and structure determination
of two new antibacterial isoquinoline alkaloids, spathullin A and B (1 and 2), from Penicillium
spathulatum Em19, along with one benzoquinone (3) formed by oxidation of 1 (Figure 1). Additionally,
the antimicrobial activities of 1 and 2 are described, as well as a proposed biosynthetic origin of
compound 1.
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Figure 1. Structures of compounds 1, 2, 3, and asperphenamate. 
2. Results and Discussion 
2.1. Isolation of Compounds 
During the screening of bacterial and fungal isolates for the production of antibacterial 
compounds, the fungus Penicillium spathulatum Em19 was found to produce two compounds with 
activity against both Gram-negative and Gram-positive bacteria. Analysis of antibacterial HPLC-
fractions by HPLC-MS suggested that the active compounds have the molecular formulae C13H11NO4 
(1) and C12H11NO2 (2), respectively, indicative of two related compounds differing by CO2. Literature 
search suggested these compounds to be previously undescribed, and the compounds were selected 
for further characterization. Following culture upscaling, extraction, gradient and isocratic 
preparative HPLC, 6.3 mg (1) and 3.5 mg (2) of the respective compounds was isolated. 
2.2. Compound Identification 
The molecular formula for compound 1, C13H11NO4, suggested a degree of unsaturation of nine. 
Eleven sp2 carbons were identified by one-dimensional 13C NMR analysis (Table 1 and Figure S2) and 
ten of these were suggested to be involved in carbon–carbon double bonds and one to be part of a 
carbonyl group (δC 162.4), indicating a tricyclic structure for 1. Data from COSY and HSQC NMR 
experiments (Figures S3 and S4) enabled the identification of two sp2 -CH-CH- spin systems (H-1/H-
2, and H-8/H-9, respectively, Figure 1), along with two isolated CH2 groups (H2-5 and H2-10). HMBC 
data (Figures 2 and S5) showed correlations between the H2-10 hydrogens and C-1 and C-9, and two 
additional sp2 carbons (C-9a and C-10a). The H2-5 hydrogens also had HMBC correlations to the sp2 
carbons C-9a and C-10a, as well as to three other sp2 carbons (C-3, C-5a and C-6). HMBC correlations 
were also observed from H-8 to two sp2 carbons (C-6 and C-7) and from H-2 to C-3. As judged by 
their chemical shifts, C-6 (δC 142.7) and C-7 (δC 143.5) were suggested to be oxygen linked. These 
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2. Results and Discussion
2.1. Isolation of Compounds
During the screening of bacterial and fungal isolates for the production of antibacterial compounds,
the fungus Penicillium spathulatum Em19 was found to produce two compounds with activity against
both Gram-negative and Gram-positive bacteria. Analysis of antibacterial HPLC-fractions by HPLC-MS
suggested that the active compounds have the molecular formulae C13H11NO4 (1) and C12H11NO2 (2),
respectively, indicative of two related compounds differing by CO2. Literature search suggested these
compounds to be previously undescribed, and the compounds were selected for further characterization.
Following culture upscaling, extraction, gradient and isocratic preparative HPLC, 6.3 mg (1) and 3.5
mg (2) of the respective compounds was isolated.
2.2. Compound Identification
The molecular formula for compound 1, C13H11NO4, suggested a degree of unsaturation of nine.
Eleven sp2 carbons were identified by one-dimensional 13C NMR analysis (Table 1 and Figure S2)
and ten of these were suggested to be involved in carbon–carbon double bonds and one to be part
of a carbonyl group (δC 162.4), indicating a tricyclic structure for 1. Data from COSY and HSQC
NMR experiments (Figures S3 and S4) enabled the identification of two sp2 -CH-CH- spin systems
(H-1/H-2, and H-8/H-9, respectively, Figure 1), along with two isolated CH2 groups (H2-5 and H2-10).
HMBC data (Figure 2 and Figure S5) showed correlations between the H2-10 hydrogens and C-1
and C-9, and two additional sp2 carbons (C-9a and C-10a). The H2-5 hydrogens also had HMBC
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correlations to the sp2 carbons C-9a and C-10a, as well as to three other sp2 carbons (C-3, C-5a and
C-6). HMBC correlations were also observed from H-8 to two sp2 carbons (C-6 and C-7) and from
H-2 to C-3. As judged by their chemical shifts, C-6 (δC 142.7) and C-7 (δC 143.5) were suggested to be
oxygen linked. These findings are in accordance with a tricyclic core structure containing a catechol
moiety and a pyrrole ring connected via two isolated CH2 groups forming a central six-membered
ring, i.e., a 5,10-dihydropyrrolo[1,2-b]isoquinoline alkaloid. The proposed core structure had three
open ends: the oxygen atoms at C-6 and C-7, and at C-3 in the pyrrole moiety, and by comparison
with the molecular formula, C-6 and C-7 were proposed to be hydroxyl substituted and C-3 to carry a
-COOH group. The presence of the latter group was in line with the presence of a carbonyl signal at δC
162.4 in the one-dimensional 13C NMR spectrum (Table 1). Thus, the structure of compound 1 was
concluded to be 6,7-dihydroxy-5,10-dihydropyrrolo[1,2-b]isoquinoline-3-carboxylic acid (Figure 1),
which was given the name spathullin A.
Table 1. NMR data for compounds 1–3 (acetone-d6, 600 and 150 MHz, 303 K).
1 2 3
Pos. δC δH, mult. (J in Hz) δC δH, mult. (J in Hz) δC δH, mult. (J in Hz)
1 105.5 6.02, d (4.0) 103.7 5.83, m 108.8 6.92, d (4.3)
2 119.0 6.97, d (4.0) 108.6 6.04, dd (3.4, 2.7) 125.8 7.64, d (4.3)
3 121.6 - 118.9 6.76, dd (2.7, 1.7) 120.8 -
5 43.4 5.54, s 43.4 5.05, br s 134.2 10.16, s
5a 120.6 - 121.0 - 119.6 -
6 142.7 - 142.6 - 179.1 -
7 143.5 - 143.3 - 181.4 -
8 115.0 6.81, d (8.1) 114.9 6.77, d (8.0) 129.3 6.48, d (10.0)
9 119.2 6.67, d (8.1) 119.4 6.65, d (8.0) 144.5 7.71, d (10.0)
9a 124.7 - 126.3 - 126.7 -
10 28.4 3.97, s 28.1 3.87, br s 121.4 7.85, s
10a 136.9 - 128.2 - 137.8 -
11 162.4 - - - n.d.a -
a n.d.: not detected.
Molecules 2019, 24, x FOR PEER REVIEW 3 of 11 
 
findings are in accordance with a tricyclic core structure containing a catechol moiety and a pyrrole 
ring connected via two isolated CH2 groups forming a central six-membered ring, i.e., a 5,10-
dihydropyrrolo[1,2-b]isoquinoline alkaloid. The proposed core structure had three open ends: the 
oxygen atoms at C-6 and C-7, and at C-3 in the pyrrole moiety, and by comparison with the molecular 
formula, C-6 and C-7 were proposed to be hydroxyl substituted and C-3 to carry a -COOH group. 
The presence of the latter group was in line with the presence of a carbonyl signal at δC 162.4 in the 
one-dimensional 13C NMR spectrum (Table 1). Thus, the structure of compound 1 was concluded to 
be 6,7-dihydroxy-5,10-dihydropyrrolo[1,2-b]isoquinoline-3-carboxylic acid (Figure 1), which was 
given the name spathullin A. 
Table 1. NMR data for compounds 1–3 (acetone-d6, 600 and 150 MHz, 303 K). 
 1 2 3 
Pos. δC δH, mult. (J 
in Hz) 
δC δH, mult. (J 
in Hz) 
δC δH, mult. (J 
in Hz) 
1 105.5 6.02, d (4.0) 103.7 5.83, m 108.8 6.92, d (4.3) 
2 119.0 6.97, d (4.0) 108.6 
6.04, dd 
(3.4, 2.7) 
125.8 7.64, d (4.3) 
3 121.6 - 118.9 
6.76, dd 
(2.7, 1.7) 
120.8 - 
5 43.4 5.54, s 43.4 5.05, br s 134.2 10.16, s 
5a 120.6 - 121.0 - 119.6 - 
6 142.7 - 142.6 - 179.1 - 
7 143.5 - 143.3 - 181.4 - 
8 115.0 6.81, d (8.1) 114.9 6.77, d (8.0) 129.3 
6.48, d 
(10.0) 
9 119.2 6.67, d (8.1) 119.4 6.65, d (8.0) 144.5 
7.71, d 
(10.0) 
9a 124.7 - 126.3 - 126.7 - 
10 28.4 3.97, s 28.1 3.87, br s 121.4 7.85, s 
10a 136.9 - 128.2 - 137.8 - 
11 162.4 - - - n.d.a - 
a) n.d.: not detected. 
 
Figure 2. Diagnostic HMBC (single headed arrows) and COSY (dashed double headed arrows) 
correlations of compounds 1 and 2. 
The formula of compound 2, C12H11NO2, differed from the formula of 1 by CO2. The 1H and 13C 
NMR data for compounds 1 and 2 are very similar (Table 1), but the 13C NMR spectrum of 2 (Figure 
S7) lacked the -COOH signal of compound 1 (δC 162.4). Instead, the 1H NMR data of 2 (Figure S6) had 
a new signal at δH 6.67 (H-3) which formed a sp2 -CH-CH-CH- spin system together with H-1 and H-
2. Thus, the data suggest that the –COOH group in compound 1 was replaced by a hydrogen in 2, 
i.e., compound 2 was 5,10-dihydropyrrolo[1,2-b]isoquinoline-6,7-diol, which was called spathullin B 
(Figure 1). 
It was found that compound 1 was spontaneously degraded to 2 in weak acidic solutions (e.g., 
0.2% formic acid in water/acetonitrile). With respect to decarboxylation, compound 1 should have 
properties similar to pyrrole-2-carboxylic acid, which has been found to decarboxylate in acidic water 
solutions already at pH 2.6 [13], which is similar to the pH of an aqueous 0.2% solution of formic acid. 
Compound 1 was also found to partly degrade when stored in acetone-d6 solutions for a few 
days at room temperature (ca 3:2 ratio for compounds 1/3). The major degradation product was a 
i re 2. iagnostic BC (single headed arro s) a S ( as e le ea e arr s)
correlations of co o n s 1 an 2.
The formula of compound 2, C12H11NO2, differed from the formula of 1 by CO2. The 1H and 13C
NMR data for compounds 1 and 2 are very similar (Table 1), but the 13C NMR spectrum of 2 (Figure S7)
lacked the -COOH signal of compound 1 (δC 162.4). Instead, the 1H NMR data of 2 (Figure S6) had
a new signal at δH 6.67 (H-3) which formed a sp2 -CH-CH-CH- spin system together with H-1 and
H-2. Thus, the data suggest that the –COOH group in compound 1 was replaced by a hydrogen in 2,
i.e., compound 2 was 5,10-dihydropyrrolo[1,2-b]isoquinoline-6,7-diol, which was called spathullin B
(Figure 1).
It was found that compound 1 was spontaneously degraded to 2 in weak acidic solutions
(e.g., 0.2% formic acid in water/acetonitrile). With respect to decarboxylation, compound 1 should have
properties similar to pyrrole-2-carboxylic acid, which has been found to decarboxylate in acidic water
solutions already at pH 2.6 [13], which is similar to the pH of an aqueous 0.2% solution of formic acid.
Compound 1 was also found to partly degrade when stored in acetone-d6 solutions for a few days
at room temperature (ca 3:2 ratio for compounds 1/3). The major degradation product was a brightly
purple-colored compound (3). Mass spectrometry suggested the molecular formula C13H7NO4 for the
compound and NMR spectroscopic investigation, including COSY, HSQC and HMBC experiments
(Figures S11–S15), showed that two sp2 linked hydrogens (H-5 and H-10) had replaced the two isolated
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CH2 groups and also dramatic shifts of the C-6 and C-7 resonances (δC 142.7 to δC 179.1 and δC
143.5 to δC 181.4, respectively). These findings suggest that compound 1 had been oxidized to the
1,2-benzoquinone 3, which was proposed the name spathullin C.
In addition to the new compounds 1–3, the known compound asperphenamate [14] (Figure 1)
was tentatively identified by HRMS-data from UHPLC-MS analysis of P. spathulatum Em19 culture
broths. The production of this compound appears to be general to P. spathulatum, as when the
species was first described, all 19 investigated isolates of the fungus were found to produce this
compound [15], and the compound has also been described to be produced in one further isolate
of P. spathulatum [16]. In addition to asperphenamate, P. spathulatum has been shown to produce an
array of different compounds, i.e., perinadine, benzomalvins, breviones, quinolactacin, cyclopenol
and related benzodiazepins, as well as a new anthraquinone [15,16], but UHPLC-MS analysis did not
suggest that any of these substances were produced by P. spathulatum Em19. Among these compounds
there are alkaloids of the quinoline, quinazoline and benzodiazepine types, but compounds 1 and 2 are
the first isoquinoline alkaloids from this fungus. Other members of the genus Penicillium have been
described to produce a number of different isoquinoline alkaloids [17–21], but alkaloids containing a
pyrrolo[1,2-b]isoquinoline structural motif, such as 1 and 2, have never been found in any fungus or
bacterium. Alkaloids with a pyrrolo[1,2-b]isoquinoline structural motif have, however, been found
in a number of different plant species, e.g., amarbellisine from the plant Amaryllis belladonna [22]
and fistulosine from the bark of Ficus fistulosa [23], but the 5,10-dihydropyrrolo[1,2-b]isoquinoline
framework of 1 and 2 is hitherto not described in any natural product.
2.3. Biosynthetic Considerations
Recently, the biosynthesis of the isoquinoline alkaloids fumisoquin A–C, by the fungus Aspergillus
fumigatus, was described by Baccile et al. [24] to be performed by enzymes encoded by NRPS-like
genes. These authors also demonstrated that fumisoquin A–C were constructed from the amino acids
serine, tyrosine and methionine, and they proposed that a carbon-carbon bond was formed between
the serine and tyrosine residues via a nucleophilic attack from dehydroalanine onto a presumed
tyrosine phosphate ester (Figure 3). Furthermore, Baccile et al. [24] described a shunt metabolite
(compound 4 in Figure 3 after thio ester hydrolysis), which is similar to compound 1, but lacks C-5 and
the central six-membered ring as well as OH-6. This suggests that compound 1 may be formed by a
similar enzymatic machinery, as outlined in Figure 3, including N-methylation of the pyrrole ring of
4, two oxidation steps, ring-closure from the nucleophilic catechol ring to the iminium moiety, and
hydrolysis of the thio ester. To investigate this, P. spathulatum Em19 cultures were fed with 1-13C-serine,
1-13C-tyrosine or 13CH3-methionine. A subsequent UHPLC-MS analysis showed that 13C label from
tyrosine and methionine indeed were incorporated into 1, suggesting that C-1, C-10a, C-10, C-9a, C-9,
C-8, C-7, C-6 and C-5a, originate from tyrosine, and C-5 from methionine (Figures 1 and 3). However,
13C label from serine was not incorporated into 1, leaving the origin of C-2, C-3 and C-11 unaccounted
for. Dehydroalanine is present in a number of natural products, e.g., nosiheptide [25] and nisin A [26],
and has, to the best of our knowledge, only been described to originate from serine residues [27,28],
but e.g., cysteine and alanine are also possible precursors of dehydroalanine. Additionally, pyruvate
could be the origin of these three carbons, via nucleophilic attack from the corresponding enolate, and
these carbons could also have a polyketide origin. To test these possibilities, Em19 cultures were fed
with 1-13C cysteine, 1-13C alanine, sodium 1-13C pyruvate or sodium 1/2-13C acetate, and were then
analysed by UHPLC-MS. These analyses show that 13C label from cysteine was incorporated into 1,
but not from alanine or pyruvate. Additionally, both sodium 1- and 2-13C acetate were incorporated
into 1, but only when 13C acetate was added from the start of cultures, and not when fed as a pulse to a
culture which was actively producing 1, as indicated by UHPLC-MS. These findings indicate that C-2,
C-3 and C-11 originate from cysteine, and that the label incorporated from 13C acetate, when added
from the start of a culture, is likely to be via the biosynthesis of cysteine from 13C acetate, and not via a
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direct polyketide-like pathway. In conclusion, the biosynthesis of compound 1 is proposed to proceed
as outlined in Figure 3, i.e., from cysteine derived dehydroalanine, tyrosine and methionine.
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2 was the more potent compound in the cytotoxicity assay (IC50 for Huh7 cells: 112 µM and 11
µM for compounds 1 and 2, respectively). The overall aim of the present study was to find new
promising antibiotic compounds for future development into new antibiotic drugs. Compounds 1 and
2 have interesting spectra of antibacterial activity, and compound 1 has a IC50/MIC ratio indicating an
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acceptable therapeutic window. However, it is a grave problem that the more cytotoxic compound 2 is
formed spontaneously from the less toxic 1. This degradation may also affect the measured MIC and
IC50 values for 1. Additionally, compounds containing catechol moieties are known to be prone to
oxidation, which indeed was found for compound 1 since it was spontaneously oxidized to compound
3 when left in acetone for a few days at room temperature. Thus, these compounds were considered
unsuitable for further evaluation for development into future antibiotic drugs.
Table 2. Minimal inhibitory concentrations (MIC) against bacteria and fungi for compounds 1 and 2,
compared to MIC for Meropenem (MEM) and Ciprofloxacin (CIP).
MIC (µg/mL)
Test Organisms 1 2 MEM CIP
Escherichia coli LMG15862 15 5 0.5 0.06
Acinetobacter baumannii
LMG1041T 15 5 2 1
Enterobacter cloacae LMG2783T 15 5 1 0.03
Klebsiella pneumonia LMG20218 64 32 1 0.5
Pseudomonas aeruginosa LMG6395 >64 64 1 0.25
Staphylococcus aureus LMG15975 4 1 0.5 0.25
Candida albicans H-29 >64 >64 n.t.a n.t.
Aspergillus fumigatus J7 >64 >64 n.t. n.t.
a not tested.
3. Materials and Methods
3.1. General Experimental Procedures
UV-spectra in MeOH were recorded on a Hitachi U-2001 spectrophotometer at room temperature.
1H and 13C NMR data were acquired at 303 K in acetone-d6 on a Bruker Avance III 600 MHz NMR
spectrometer (Bruker Biospin GmBH, Rheinstetten, Germany) equipped with a 5-mm cryo-probe
(1H, 13C, 15N, 31P). Standard pulse sequences supplied by Bruker were used for the determination
of 1H and 13C chemical shifts and connectivities. For structure elucidation, 1D 1H, 1D 13C, COSY,
DEPT-HSQC and HMBC were applied. Chemical shifts were determined relative to signals from
residual acetone-d5 (δH 2.05) and acetone-d6 (δC 29.8). HPLC-MS was performed on an Agilent 1100
HPLC (Agilent, Palo Alto, CA, USA) connected to a maXis Impact ESI-QTOF MS (Bruker Daltonic
GmbH., Bremen, Germany), and UHPLC-MS was done on an Agilent 1290 Infinity II connected to the
same mass spectrometer. Preparative HPLC was performed on a Gilson 306/306 pump system (Gilson
Inc., Middleton, WI, USA) with a Gilson 119 UV/VIS detector monitoring at 210 nm. Fractions were
collected using a Gilson 204 fraction collector in 2.2-mL square well plates (Porvair Sciences Ltd.,
King’s Lynn, UK). MeCN of HPLC gradient grade (Sigma-Aldrich, St. Louis, MO, USA) and deionized
filtered water (Millipore, Billerica, MA, USA) were used for mobile phases.
3.2. Strain Origin, Identity and Maintenance
The isolate of P. spathulatum strain Frisvad and Samson strain Em19 was isolated from a sample of
Grottmans Bat Guano (Sneckenströms Ekohandel, Surte Sweden) purchased in Sweden but originating
from the Philippines. The strain was isolated and purified on Malt Extract Agar [MEA, 15 g Malt
Extract (BD Difco Ltd., Detroit, MI, USA), 15 g Bacto Agar (BD Difco Ltd.) in 1 L deionized water].
The strain Em19 was identified as P. spatulathum [15] by sequencing the internal transcribed spacer
region (ITS1, 5.8S, ITS2; GenBank accession number MN759659) using the primers ITS1/ITS4 [30].
DNA was extracted and purified from fungal mycelium with the FastDNA spin kit for soil (MP
Biomedicals/Fisher Scientific) according to the manufacturer’s instructions. Sequencing was done
by Macrogen (EZ-seq, Macrogen Europe, Amsterdam, the Netherlands). The strain was initially
maintained as an actively growing colony at MEA plate(s) in darkness at 20 ◦C and after first culturing
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as frozen/deep-frozen (−20 ◦C/−70 ◦C) stocks of ME grown mycelium/spores mixed with 20–25%
glycerol. If needed, the strain was transferred to MEA plates for starting new cultures, otherwise new
cultures were started directly from frozen stocks.
The strains of Escherichia coli LMG15862 (E. coli), Acinetobacter baumannii LMG1041T
(A. baumannii), Enterobacter cloacae LMG2783T (E. cloacae), Klebsiella pneumoniae LMG20218
(K. pneumoniae), Pseudomonas aeruginosa LMG6395 (P. aeruginosa) and Staphylococcus aureus
LMG15975 (S. aureus) were purchased from the Belgian Co-ordinated Collections of Micro-organisms,
Gent, Belgium. The origin and cell/spore production of the strains of the yeast Candida albicans
(C.P. Robin) Berkhout (C. albicans) strain H-29 and the fungus Aspergillus fumigatus Fres. strain J7
(A. fumigatus), was as previously described [31]. All strains were maintained as advised by the culture
collections and cells/spores of all strains were stored at −70 ◦C.
3.3. Culture Conditions and Metabolite Sampling
During primary screening for antimicrobial activity, cultures of the strain Em19 (150 mL in 500 mL
Erlenmeyer flasks) were grown in two liquid substrates: 1) Malt Extract [ME; 15 g Malt Extract (BD
Difco Ltd.) in 1000 mL deionized H2O] and 2) in modified Mineral Medium pH 5.7 (MM-pH 5.7) for
Pseudomonas [32,33] supplemented with 50 mL of Hagem Medium [34] [HM, 5 g ME (BD Difco Ltd.),
5 g glucose, 0.5 g KH2PO4, 0.5 g MgSO4 × 7 H2O, 0.5 g NH4Cl, 5 mL of Fe-EDTA stock (1.28 g FeSO4,
1.72 g EDTA, 1 L deionized water) in 1 L deionized water] and 250 mL Potato Dextrose Broth [PDB, 24 g
Potato Dextrose Broth (BD Difco Ltd.)]. Potassium-sodium phosphate buffer (40 mL, 0.5 M, pH 5.7) was
used to achieve the desired pH of the MM-pH 5.7 medium. The MM-pH 5.7 (700 mL), HM and PDB
media were sterilized separately and prior to culturing, mixed to the MM-HMPDB-pH 5.7 medium
composed of MM, HM, PDB and additionally supplemented with 2% glycerol. The 150 mL of ME
cultures for prescreening were started by cutting around 20–25 small pieces from actively growing MEA
Em19 culture and inoculating them into a ME containing Erlenmeyer flask. The MM-HMPDB-pH 5.7
cultures were started by transferring 10 mL of 72–96 h-old ME culture per 150 mL MM-HMPDB-pH 5.7.
For upscaling the production of selected active metabolites, the strain was cultured in
MM-HMPDB-pH 5.7 (10 × 150 mL in 500 mL Erlenmeyer flasks) and to each culture, 10 mL of
72/96 h old ME start culture of Em19 was transferred for inoculation. Cultures were incubated on a
rotary shaker (120/130 rpm) for 14–21 days at 15/20 ◦C in the dark.
To collect extracellular metabolites, one sterile nylon bag with the polymeric resin Amberlite XAD
16 (Sigma-Aldrich), approximately 8 g wet weight per bag, was added to each actively growing 150 mL
culture, 72 to 96 h after inoculation.
For labeling with 13C labelled substrates, 18 mL MM-HMPDB-pH 5.7 in 125 mL Erlenmeyer flasks
was inoculated with 2 mL of 72/96 h old ME start cultures of P. spathulatum. Prior to labelling, cultures
were incubated on a rotary shaker (120 rpm) at 15 ◦C in the dark. After 96 h, 20 mg of 1-13C serine
(CIL, Cambridge Isotope Laboratories Inc., Tewksbury, MA, USA), 1-13C cysteine (CIL), 1-13C tyrosine
(CIL), 13CH3 methionine (CIL), sodium 1-13C pyruvate (Sigma-Aldrich, St. Louis, MO, USA), sodium
1-13C acetate (Sigma-Aldrich), or sodium 2-13C acetate (Sigma-Aldrich), was added to cultures together
with one sterile nylon bag containing approximately 2 g wet weight Sepabeads® SP850 (Mitsubishi
Chemical Co., Tokyo, Japan). Em19 cultures were afterwards incubated on a rotary shaker (120 rpm)
for 7–8 days at 15 ◦C in the dark, and then the adsorbent bags were washed with deionized H2O to
remove fungal debris and extracted with 2 mL of MeOH prior to UHPLC-MS analysis (as below).
3.4. Isolation of Compounds 1 and 2
The adsorbent bag was removed from a liquid culture of P. spathulatum (150 mL) after three
weeks of cultivation. The bag was washed with deionized H2O, and then extracted with 2 × 10 mL of
methanol and 2 × 10 mL MeCN. The extracts were pooled and dried under nitrogen and re-dissolved
in 1.0 mL 50% MeCN, and fractionated by gradient reversed phase preparative HPLC (21.2 × 100 mm,
5 µm, Hypersil Gold, Thermo Scientific, Waltham, MA, USA) by applying a linear gradient of 10–95%
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MeCN in 10 min, followed by a 10 min hold at 95% aq. MeCN (flow 10 mL/min). Fractions were
assayed for antibacterial activity and analysed by HPLC-MS as described below.
To obtain more of compounds 1 and 2, ten liquid cultures of P. spathulatum (each 150 mL) were
extracted using adsorbent bags (Amberlite XAD 16) as above. The combined and dried extracts were
re-dissolved in 150 mL 20% MeCN and subsequently loaded onto 3 × 10 g C18 SPE columns. Each
SPE column was washed with 50 mL 20% MeCN and then eluted with 50 mL 95% MeCN. The 95%
MeCN extract was dried under reduced pressure, re-dissolved in 4 mL 50% MeCN and fractionated by
gradient reversed phase preparative HPLC (as above). Fractions containing crude compound 1 and 2,
as indicated by HPLC-MS (as below), were individually pooled and dried under reduced pressure.
The respective samples were dissolved in 1 mL eluent (as below) before further purification using
reversed phase preparative HPLC (column and flow as above) at isocratic conditions with aqueous
30% and 40% MeCN, respectively. Following an analysis by HPLC-MS (as below), fractions containing
compounds 1 and 2 were pooled and dried to yield 6.3 mg of 1 and 3.5 mg of 2.
Spathullin A (1, 6,7-dihydroxy-5,10-dihydropyrrolo[1,2-b]isoquinoline-3-carboxylic acid): Spathullin A was
obtained as white amorphous solid. UV λmax (MeOH) nm (log ε): 206, 274 (4.45, 4.11); NMR-data, see
Table 1; HRMS: m/z 246.0762 [M + H]+ (calcd. for C13H12NO4, 246.0761).
Spathullin B (2, 5,10-dihydropyrrolo[1,2-b]isoquinoline-6,7-diol): Spathullin B was obtained as colorless oil.
UV λmax (MeOH) nm (log ε) 206, 282 (4.48, 3.49); NMR-data, see Table 1; HRMS: m/z 202.0861 [M + H]+
(calcd. for C12H12NO2, 202.0863).
Spathullin C (3, 6,7-dioxo-6,7-dihydropyrrolo[1,2-b]isoquinoline-3-carboxylic acid): Spathullin C was obtained
as purple amorphous solid. NMR-data, see Table 1; HRMS: m/z 242.0451 [M + H]+ (calcd. for C13H8NO4,
242.0448).
3.5. In Vitro Bioassay
Chromatographic fractions during primary screening were assayed for antimicrobial activity
using an earlier developed protocol (“Microtiter plate assay 2”) [35], which is based on the inhibition
of cell growth or spore germination in microtiter plates. The following organisms were used for the
bioassays: E. coli, A. baumannii, E. cloacae, K. pneumoniae, P. aeruginosa, S. aureus, C. albicans and A.
fumigatus. Aliquots of HPLC fractions were transferred to 96-well microtiter plates and the solvent was
evaporated in a fume-hood overnight. Cell suspensions (all bacterial strains and C. albicans) or spore
suspensions (A. fumigatus), 100 µL at a concentration of 104 cells/spores per mL, in VBP for bacteria, ME
for A. fumigatus, and Yeast Extract—Malt Extract Medium, ISP2 [36], (4 g Yeast Extract (BD Difco Ltd.),
10 g Malt Extract (BD Difco Ltd.), 4 g dextrose in 1 L deionized water) for C. albicans, were added to the
wells and incubated at 37 ◦C in the dark for 16 to 24 h. The effect on the bacterial/fungal growth was
estimated visually according to the following scale: 3—full growth inhibition, 2—intermediate growth
inhibition, 1—weak growth inhibition, 0—no growth inhibition. Positive controls were cell/spore
suspensions only, and sterile medium was used as negative control. Further steps of purification of
compounds 1 and 2 were done with S. aureus as the activity indicator.
3.6. Analysis by HPLC-MS and UHPLC-MS
Culture extracts and HPLC fractions were analyzed by HPLC-MS on a reversed phase HPLC
column (3.0 × 50 mm, 2.6 µm, Accucore RP-MS, Thermo Scientific, Waltham, MA, USA), using a
gradient of MeCN in water (10–95% MeCN in 3 min, 95% MeCN for 4 min, at 0.8 mL/min, with
0.2% formic acid). 13C-labelling experiments were analyzed by UHPLC-MS on a reversed phase
UHPLC column (2.1 × 50 mm, 1.5 µm, Thermo Accucore Vanquish RP-MS, Thermo Scientific, Waltham,
MA, USA), using a gradient of MeCN in water (10–95% MeCN in 3 min, 95% MeCN for 1.2 min, at
0.9 mL/min, with 0.2% formic acid). For both HPLC-MS and UHPLC-MS, the mass spectrometer was
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operated in positive mode with scanning of m/z 50–1500, and calibration of the mass spectra was
obtained by using sodium formate clusters.
3.7. MIC Determination
The MIC of all compounds was measured by means of a broth micro-dilution method in 96-well
microtiter plates using all organisms used in the in vitro bioassay. The test media were AM3 Broth (BD
Difco Ltd.) mixed with phosphate buffered saline (PBS, Amresco LLC, Solon, OH, USA) in 1:4 ratio
(E. coli, A. baumannii, E. cloacae, K. pneumoniae and P. aeruginosa), AM3 Broth mixed with PBS in 1:1
ratio (S. aureus), ME (A. fumigatus) and for C. albicans ISP2. Prior to MIC-tests, the cell concentration
of tested bacterial/fungal pathogens was adjusted to between 1 and 5 × 105 cells/spores per mL. Cell
concentration was confirmed by colony counting after diluting and plating the respective bacterial
pathogen on Vegetable Peptone Broth agar plates (VPA, 10 g Vegetable Peptone Broth (Oxoid Ltd.,
Basingstoke, UK), 15 g Bacto Agar (Difco Ltd., Tyrone) in 1 L deionised water) directly after each of
MIC-tests. The cells of C. albicans were plated on ISP2 agar plates (ISP2, 15 g Bacto Agar (Difco Ltd.) in
1 L deionised water) and respectively spores of A. fumigatus were plated on MEA plates. Plates were
subsequently incubated at 37 ◦C in the dark, and viable colonies counted after 16 to 24 h. To estimate
MIC values (concentration range between 0.05 and 50 µg/mL), solutions of the tested compounds (100,
10 and 1 and if needed 0.1 µg/mL in MeOH) were dispensed into wells of microtiter plate(s) and the
solvent was evaporated in a fume-hood. Subsequently, suspensions of pathogen cells in the appropriate
medium were dispensed to the wells of microtiter plates and the growth of pathogens was observed
after 16 to 20 h of incubation at 37 ◦C in the dark. Positive controls were the respective pathogen cells
suspended in untreated sterile media without addition of compounds(s) and negative controls were
the media only. MIC values were defined as the lowest concentration of each compound with no
visible growth of pathogen. All MIC tests were performed in triplicate and repeated at least twice.
3.8. Determination of Toxicity
Huh-7 cells (hepatocellular carcinoma cells, ReBLikon GmbH, Schriesheim, Germany) were
passaged into 96-well microplates (2 × 104 cells/well) followed by the addition of the test substances
the next day, in duplicate samples. The number of viable cells was determined after 48 h by using a
soluble formazan (XTT) assay [37] and the compound troxacitabine was used as positive control.
Supplementary Materials: The following are available online, Figure S1: 1H NMR (acetone-d6, 600 MHz)
spectrum of 1. Figure S2: 13C NMR (acetone-d6, 150 MHz) spectrum of 1. Figure S3: COSY NMR (acetone-d6)
spectrum of 1. Figure S4: HSQC NMR (acetone-d6) spectrum of 1. Figure S5: HMBC NMR (acetone-d6) spectrum
of 1. Figure S6: 1H NMR (acetone-d6, 600 MHz) spectrum of 2. Figure S7: 13C NMR (acetone-d6, 150 MHz)
spectrum of 2. Figure S8: COSY NMR (acetone-d6) spectrum of 2. Figure S9: HSQC NMR (acetone-d6) spectrum
of 2. Figure S10: HMBC NMR (acetone-d6) spectrum of 2. Figure S11: 1H NMR (acetone-d6, 600 MHz) spectrum
of 3. Integral values shown for signals from compound 3, the other signals belong to compound 1, the solvent or
residual amounts of methanol. Figure S12: 13C NMR (acetone-d6, 150 MHz) spectrum of 3. Shift values shown
for carbons from compound 3, remaining signals belong to compound 1. Figure S13: COSY NMR (acetone-d6)
spectrum of 3. Figure S14: HSQC NMR (acetone-d6) spectrum of 3. Figure S15: HMBC NMR (acetone-d6) spectrum
of 3. Figure S16: HRMS base peak chromatogram of the mixture of compound 3 (2.6 min—m/z 242.0451) and
compound 1 (3.0 min—m/z 246.0762). Figure S17: HR mass spectrum of compound 1, m/z 246.0762 [M + H]+
(calcd. for C13H12NO4, 246.0761). Figure S18: HR mass spectrum of compound 2, m/z 202.0861 [M + H]+ (calcd.
for C12H12NO2, 202.0863). Figure S17: HR mass spectrum of compound 3, m/z 242.0451 [M + H]+ (calcd. for
C13H8NO4, 242.0448).
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